Zai Lab Limited (ZLAB) - News Archive

In a significant milestone for cancer research and therapy, Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) has announced that a late-breaking abstract highlighting updated data from its global Phase 1 clinical trial of zoci...

In recent developments within the biotechnology sector, Zai Lab Limited (NASDAQ: ZLAB) has emerged as a focal point for both investor scrutiny and competitive analysis. The Pomerantz Law Firm has initiated an investigat...

Zai Lab Limited, a burgeoning pharmaceutical company with listings on NASDAQ (ZLAB) and the Hong Kong Stock Exchange (9688), is set to enhance its visibility and investor engagement through participation in key investor...

In recent developments within the healthcare sphere, Zai Lab Limited (NASDAQ: ZLAB) and Novocure Limited (NASDAQ: NVCR) have announced significant results from their Phase 3 PANOVA-3 trial, which investigated the effica...

Zai Lab Limited, a global biopharmaceutical company, is making significant strides in the field of oncology through a series of clinical trials and regulatory achievements, particularly in small cell lung cancer (SCLC)...

In a recent press release, Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) made a significant announcement regarding the acceptance of its supplemental New Drug Application (sNDA) for repotrectinib by China s National Medica...

The realm of pancreatic cancer treatment has witnessed a promising breakthrough with the recent announcement of positive topline results from the Phase 3 PANOVA-3 clinical trial. This trial is a collaborative venture be...

In a significant advancement for both healthcare access and cancer treatment in China, Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced the inclusion of AUGTYRO (repotrectinib) in the recently updated National Reimb...

Zai Lab Limited Prices Public Offering Amidst Strong Revenue Growth and Competitive LandscapeIn a significant move to bolster its financial standing, Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a leading biopharmaceutic...

Zai Lab Limited, a prominent biopharmaceutical company, is poised to make significant contributions to the treatment landscape in oncology and infectious diseases. This article summarizes key developments from Zai Lab,...

In recent years, Zai Lab Limited has consistently positioned itself at the forefront of medical advancements, championing the development of innovative treatments in oncology and bacteriology. This article delves into t...

Zai Lab Limited, a leading biopharmaceutical company, has recently published a study in the renowned journal Cell, which sheds new light on the treatment of homologous recombination deficiency (HRD) positive ovarian can...

Zai Lab and Innoviva Specialty Therapeutics Gain NMPA Approval for New Drug XACDURO for Treating Serious Pneumonia in ChinaSHANGHAI & CAMBRIDGE, Mass. & WALTHAM, Mass. - Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and In...

Zai Lab Limited, a renowned biopharmaceutical company listed on NASDAQ (ZLAB) and HKEX (9688), recently announced that the National Medical Products Administration (NMPA) in China has granted approval for their New Drug...

Zai Lab Limited, a leading biopharmaceutical company, has recently revealed the highly anticipated results from the Phase 3 NORA study, evaluating the efficacy and safety of their innovative drug, ZEJULA (niraparib), in...

Zai Lab s Repotrectinib Shows Promising Results in Treating ROS1 Fusion-Positive NSCLC, Published in The New England Journal of MedicineShanghai and Cambridge, Mass. - Zai Lab Limited, a leading biopharmaceutical compan...

In a path-forward moment for Zai Lab Limited, the biotech firm announced today that the 2023 National Reimbursement Drug List (NRDL), released by China s National Healthcare Security Administration (NHSA), now includes...